Taurine Eye Drops May Prevent the Progression of Cataract

December 4, 2024 updated by: Atheer Zgair, University Of Anbar

Taurine Affects the Progression of Senile Cataract: a Single-arm Pre-post Intervention Study

The aim of the current intervention study is to determine the effectiveness of taurine containing eye drops (available under brand name VIZILOTON) to prevent the progression of grade I and II senile cataract.

This study could answer:

  • Dose continuous use of taurine-containing eye drops could prevent further deterioration of vision in mild cases of cataract?
  • The acceptance/ compliance of participants to taurine-containing eye drops.
  • Could long-term use of taurine-containing eye drops cause adverse effect(s)?

Participants will:

  • Take taurine-containing eye drops (VIZILOTON eye drops) 4 times a day for one year.
  • Visit eye clinic every 3 months for assessment and visual examination.
  • Keep notes for their symptoms and their adherence to treatment.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

50

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Iraq
    • Anbar
      • Ramadi, Anbar, Iraq, 31001
        • Al-Nahrain Eye Clinics

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • The presence of grade I or II senile cataract on one or two eyes.

Exclusion Criteria:

  • clinical signs of glaucoma
  • history of amblyopia, eye surgery, argon or YAG laser eye treatment, or major eye trauma
  • history of iritis, retinal crystalline deposits, or optic nerve disease
  • visually significant fundus pathology

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Application of Taurine-containing Eye Drops
Drug: Taurine
Taurine-containing eye drops (VIZILOTON) are applied 4 times daily for a period of one year
Other Names:
  • VIZILOTIN Eye Drops

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Visual Acuity
Time Frame: 1 Year
1 Year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Of Anbar

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 10, 2023

Primary Completion (Estimated)

December 20, 2024

Study Completion (Estimated)

December 20, 2024

Study Registration Dates

First Submitted

October 10, 2024

First Submitted That Met QC Criteria

October 10, 2024

First Posted (Actual)

October 15, 2024

Study Record Updates

Last Update Posted (Estimated)

December 9, 2024

Last Update Submitted That Met QC Criteria

December 4, 2024

Last Verified

December 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • UOANBAR-170

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cataract

Clinical Trials on Taurine

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe